Seeking Alpha

Privately held Ocera Therapeutics (a developer of liver disease treatments) will merge with a...

Privately held Ocera Therapeutics (a developer of liver disease treatments) will merge with a subsidiary of Tranzyme Pharmaceuticals (TZYM) in an all-stock deal. The companies say the merged entity (which will assume the "Ocera" name and will be 72.6% owned by Ocera shareholders) will be a NASDAQ-listed company. Tranzyme will issue $20M in common stock and effect a reverse stock split concurrently with the closing of the deal. (See: TZYM to evaluate alternatives)
From other sites
Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs